Status:
COMPLETED
Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type II Diabetes
Lead Sponsor:
Vinmec Research Institute of Stem Cell and Gene Technology
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of autologous bone marrow-derived mesenchymal stem cells transplantation in the treatment of type 2 diabetes mellitus
Detailed Description
Bone marrow-derived mesenchymal stem cells have the immunosuppressive effect and secrete a variety of cytokines, improve the microenvironment of diabetic patients, targeting insulin resistance tissue,...
Eligibility Criteria
Inclusion
- Males and females
- Age from 18 years and above.
- Hemoglobin A1c (HbA1c) is ranged from 7.5% to 9% at baseline.
- Type 2 diabetes duration 5 years or more.
- Before the screening, joint or combined with insulin, oral medications to treat more than 3 months.
- Who signed the informed consent form.
Exclusion
- Type 1 diabetes.
- Chronic disease or severe disease, including cancer, severe heart disease, kidney disease, liver disease, etc.
- According to the medical doctor's judgement, may endanger the safety of the subjects
Key Trial Info
Start Date :
November 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2019
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03343782
Start Date
November 1 2017
End Date
August 1 2019
Last Update
June 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vinmec Research Institute of Stem Cell and Gene Technology
Hanoi, Vietnam, 10000